Dietary phosphorus, serum phosphorus, and cardiovascular disease

Annals of the New York Academy of Sciences

Volumn 1301, Issue 1, 2013, Pages 21-26

  Menon, Madhav C ^a   Ix, Joachim H ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Cardiovascular disease; Chronic kidney disease; Dietary; Phosphorus; Serum

Indexed keywords

CALCIUM; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS; SODIUM PHOSPHATE COTRANSPORTER;

ADVERSE OUTCOME; ARTICLE; BIOAVAILABILITY; CALCIUM BLOOD LEVEL; CALORIC INTAKE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY DISEASE; DIET RESTRICTION; DIET SUPPLEMENTATION; DIETARY INTAKE; FOLLOW UP; HUMAN; HYPERPHOSPHATEMIA; INTESTINE ABSORPTION; KIDNEY FAILURE; KIDNEY FUNCTION; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PHYSICAL ACTIVITY; PROTEIN RESTRICTION; STEADY STATE; URINARY EXCRETION;

CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DIETARY; PHOSPHORUS; SERUM;

CARDIOVASCULAR DISEASES; HUMANS; PHOSPHATES; PHOSPHORUS, DIETARY; RENAL INSUFFICIENCY, CHRONIC;

EID: 84885485691     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12283     Document Type: Article

References (41)

1. Block, G.A. et al. 2004. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J. Am. Soc. Nephrol. 15: 2208-2218.
2. Tentori, F. et al. 2008. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am. J. Kidney Dis. 52: 519-530.
3. Dhingra, R. et al. 2007. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch. Intern. Med. 167: 879-885.
4. Ix, J.H. et al. 2009. Serum phosphorus concentrations and arterial stiffness among individuals with normal kidney function to moderate kidney disease in MESA. Clin. J. Am. Soc. Nephrol. 4: 609-615.
5. Meng, J. et al. 2010. Serum phosphorus levels and the spectrum of ankle-brachial index in older men: the Osteoporotic Fractures in Men (MrOS) study. Am. J. Epidemiol. 171: 909-916.
6. Antoniucci, D.M., T. Yamashita & A.A. Portale 2006. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J. Clin. Endocrinol. Metab. 91: 3144-3149.
7. Palmer, S.C. et al. 2011. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. J. Am. Med. Assoc. 305: 1119-1127.
8. Chen, N.X. et al. 2002. Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney Int. 62: 1724-1731.
9. Shuto, E. et al. 2009. Dietary phosphorus acutely impairs endothelial function. J. Am. Soc. Nephrol. 20: 1504-1512.
10. Six, I. et al. 2012. Effects of phosphate on vascular function under normal conditions and influence of the uraemic state. Cardiovasc. Res. 96: 130-139.
11. Faul, C. et al. 2011. FGF23 induces left ventricular hypertrophy. J. Clin. Invest. 121: 4393-4408.
12. Gutierrez, O.M. et al. 2008. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N. Engl. J. Med. 359: 584-592.
13. Tonelli, M. et al. 2005. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 112: 2627-2633.
14. Shioi, A. et al. 1995. Beta-glycerophosphate accelerates calcification in cultured bovine vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 15: 2003-2009.
15. Steitz, S.A. et al. 2001. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ. Res. 89: 1147-1154.
16. Mathew, S. et al. 2008. The mechanism of phosphorus as a cardiovascular risk factor in CKD. J. Am. Soc. Nephrol. 19: 1092-1105.
17. Chen, N.X. & S.M. Moe 2012. Vascular calcification: pathophysiology and risk factors. Cur. Hypertension Rep. 14: 228-237.
18. Criqui, M.H. et al. 2010. Risk factor differences for aortic versus coronary calcified atherosclerosis: the multiethnic study of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 30: 2289-2296.
19. Foley, R.N. et al. 2009. Serum phosphorus levels associate with coronary atherosclerosis in young adults. J. Am. Soc. Nephrol. 20: 397-404.
20. Gonzalez-Parra, E. et al. 2012. Phosphate: a stealthier killer than previously thought? Cardiovasc. Pathol 21: 372-381.
21. Moe, S.M. et al. 2011. Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 6: 257-264.
22. Block, G.A. et al. 2012. Effects of phosphate binders in moderate CKD. J. Am. Soc. Nephrol. 23: 1407-1415.
23. Isakova, T. et al. 2008. Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD. J. Am. Soc. Nephrol. 19: 615-623.
24. Silver, J. et al. 1999. Regulation of the parathyroid hormone gene by vitamin D, calcium and phosphate. Kidney Int. Suppl. 73: S2-S7.
25. Gonzalez-Parra, E. et al. 2011. Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients. Nephrol. Dial. Transplant. 26: 2567-2571.
26. Lopes, A.A. et al. 2012. Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status. Am. J. Kidney Dis. 60: 90-101.
27. Berndt, T. et al. 2007. Evidence for a signaling axis by which intestinal phosphate rapidly modulates renal phosphate reabsorption. Proc. Natl. Acad. Sci. U. S. A. 104: 11085-11090.
28. Hruska, K.A. et al. 2008. Hyperphosphatemia of chronic kidney disease. Kidney Int. 74: 148-157.
29. Markowitz, M., L. Rotkin & J.F. Rosen 1981. Circadian rhythms of blood minerals in humans. Science 213: 672-674.
30. Ix, J.H. et al. 2011. Sustained hypophosphatemic effect of once-daily niacin/laropiprant in dyslipidemic CKD stage 3 patients. Am. J. Kidney Dis. 57: 963-965.
31. Isakova, T. et al. 2009. Phosphorus binders and survival on hemodialysis. J. Am. Soc. Nephrol. 20: 388-396.
32. Newsome, B. et al. 2013. Effect of protein restriction on serum and urine phosphate in the Modification of Diet in Renal Disease (MDRD) study. Am. J. Kidney Dis. 61: 1045-1046.
33. Palomino, H.L. et al. 2013. 24-hour urine phosphorus excretion and mortality and cardiovascular events. Clin. J. Am. Soc. Nephrol. 8: 1202-1210.
34. de Boer, I.H., T.C. Rue & B. Kestenbaum 2009. Serum phosphorus concentrations in the third National Health and Nutrition Examination Survey (NHANES III). Am. J. Kidney Dis. 53: 399-407.
35. Uhlig, K. et al. 2010. KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). Am. J. Kidney Dis. 55: 773-799.
36. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. 2009. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. Suppl. 113: S1-S130.
37. Murtaugh, M.A. et al. 2012. Dietary phosphorus intake and mortality in moderate chronic kidney disease: NHANES III. Nephrol. Dial. Transplant. 27: 990-996.
38. Menon, V. et al. 2009. Effect of a very low-protein diet on outcomes: long-term follow-up of the Modification of Diet in Renal Disease (MDRD) study. Am. J. Kidney Dis. 53: 208-217.
39. Burnett, S.M. et al. 2006. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J. Bone Miner. Res. 21: 1187-1196.
40. Isakova, T. et al. 2013. Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD. Clin. J. Am. Soc. Nephrol. 8: 1009-1018.
41. Kremsdorf, R.A. et al. 2013. Effects of a high-protein diet on regulation of phosphorus homeostasis. J. Clin. Endocrinol. Metab. 98: 1207-1213.